fbpx

InVivo Biosystems Blog

Home > Blog > Drug Repurposing for Neurological Disorders

Drug Repurposing for Neurological Disorders

Summary

Neurological disorders are extremely widespread, affecting over 1 billion people worldwide, and have debilitating effects, impacting the brain, spinal cord, cranial nerves, and peripheral nerves. Despite this, many neurological disorders lack effective treatment. One strategy that offers an attractive way to find better therapies is drug repurposing. Also known as drug reprofiling or drug repositioning, drug repurposing identifies new purposes for pre-existing compounds, and offers reduced time frames, decreased costs, and improved success rates. While drug repurposing for neurological disorders has gained attention in the past decade, it is still an underused approach. In this article we will discuss drug repurposing, its benefits, its place in neurological drug research, and its recent success.

In the USA alone over 100 million people suffer from a neurological condition, many without adequate treatment. For instance, while there are over 30 antiepileptic drugs on the market, 30-40% of epileptic patients find these medications don’t help control their seizures (Mao, 2020; Wood, 2019). Developing new drugs, however, is costly and time consuming – especially for central nervous system (CNS) therapies which have a notoriously high failure rate (Butlen-Ducuing et al., 2016). Alternatively, drug repurposing (i.e. finding novel uses for existing drugs) can be used to help provide better, much needed therapies. 

Drug repurposing: What is it?

Drug repurposing (DR) is a strategy that enables previous research to not sit underutilized. Instead, previous findings can be applied to different diseases. There are two approaches to drug repurposing: on-target and off-target. On-target drug repurposing is when the repurposed drug acts on the same biological target as the original drug but is applied to a different disease.  Off-target, on the other hand, is when the repurposed drug is aiming to have a therapeutic effect, but its pharmacological mechanism is unknown. [Figure 1] (Clout et al., 2019; Rudrapal, Khairnar &  Jadhav,  2020). An example of a successful on-target drug repurposing campaign is the drug Minoxidil. Minoxidil was developed to treat high blood pressure, but is now sold to treat certain types of baldness – because the drug works by opening potassium channels and widening blood vessels, which improves blood flow, but also gets more nutrients to hair follicles (Bryan, 2011). Aspirin, however, is an example of an off-target drug as it is used to treat a variety of afflictions without its ability to produce an effect being fully understood.

Figure 1. The different strategies of drug repurposing: on-target and off-target (Oliveira & Lang, 2018)

Figure 1. The different strategies of drug repurposing: on-target and off-target (Oliveira & Lang, 2018)

Regardless of whether these repurposed drugs are discovered serendipitously, through computational screening, or through targeted experiments, being able to optimize already developed drugs is very valuable. Drug repurposing makes it more likely that better therapies will be found. Moreover, drug repurposing can facilitate the discovery of rare disease therapies, because drugmakers consider developing a new drug for rare diseases to have a bad risk-reward ratio: too costly for the small number of people the drugs would affect. With this in mind, policymakers in the USA and around the world, have tried to promote drug repurposing by creating incentives, such as giving a drug company market exclusivity for the repurposed drug (3 years for most drugs, and 7 years for rare disease drugs) (Sahragardjoonegani, et al. 2021). 

Figure 2. Process of traditional drug discovery vs. drug repurposing

Figure 2. Process of traditional drug discovery vs. drug repurposing (Rudrapal, Khairnar, & Jadhav, 2020).

 

What are the advantages of drug repurposing?

Figure 3. The typical pipeline for getting a new drug to market compared to a repurposed drug (Clout et al., 2019).

Figure 3. The typical pipeline for getting a new drug to market compared to a repurposed drug (Clout et al., 2019).

It has been reported that, on average, it costs $500 million to bring a new drug to market, and 7-10 years (Ogbru, 2020). When drugs are repurposed, however, total development costs can be reduced by 50% and their time frame can be cut significantly (Bauzon, Lee & Cummings, 2020). Why is there such a staggering difference? The main reason therapies fail during development is because they don’t pass safety guidelines, but since drug repurposing uses FDA-approved drugs that have already undergone human trials, they are already proven to be safe. Repurposed drugs have the advantage of already going through the preclinical, and Phase 1 steps of drug development where efficacy, toxicity, tolerability, and pharmacokinetics are thoroughly tested [Figure 3] (Clout et al., 2019). This allows repurposed drugs to bypass these stages in the development pipeline, saving both time and money. Furthermore, repurposed drugs have a better chance of making it to market: while ~10% of new drug applications gain market approval, ~30% of repurposed drugs are approved (Hernandez et al., 2017). These numbers show just how impactful repurposing can be – building upon previous research repurposed drugs can gain a speedy, and often more successful, review by the FDA. It is worth mentioning that just because a drug has been repurposed does not mean that it has failed its original intention. In fact, many drugs are currently being utilized as therapies for multiple diseases, for instance adalimumab (Humira) was originally approved with one purpose and now has ten, and onabotulinumtoxinA (Botox) was approved for two uses and has nine current uses (Sahragardjoonegani et al., 2021). 

 

How does it work for finding neurological disease therapies?

Some disease research fields have adopted drug repurposing more widely than others. For instance, repurposing is popular in Neurological and Psychiatric disorder research, with repurposed drugs accounting for 39% of all drugs currently being developed to treat Alzheimer’s disease (AD) (Bauzon, Lee & Cummings, 2020). Neurological diseases include: neurogenetic diseases (such as Huntington’s disease and muscular dystrophy), developmental disorders (such as cerebral palsy), degenerative diseases of adult life (such as Parkinson’s disease and Alzheimer’s disease), metabolic diseases (such as Gaucher’s disease), and convulsive disorders (such as epilepsy), just to name a few (NIH, 2021). The high number of repurposed drugs in neurological disease research can partially be attributed to how attractive the financial advantages are for drug repurposing because, as previously mentioned, CNS drug development has a high failure rate. However, the popularity of the repurposing approach is predominantly due to how the field of neurology has developed. Historically, neurological disease research and diagnosis has relied on a person’s disease attributes (the clinical phenotype) without fully understanding the processes behind them (Clout et al., 2019). Because of this, therapies for neurological diseases took an off-target approach, treating the symptoms of the disease without a thorough understanding of the underlying mechanisms, which often led to unintended side-effects. While that can sound alarming, it is actually very beneficial in disease research: this lack of specificity in the drug’s target allows these therapies to treat other disorders in the same therapeutic area (Clout et al., 2019).

As advances have been made in our understanding of how genes impact disease, more researchers have begun applying an on-target approach to neurological and psychiatric disorder research.. Studies of co-expression networks and genome-wide association studies have revealed how many disease-associated genes are shared between these disorders [Figure 4] (Lüscher Dias et al., 2020). A repurposing drug strategy, whether on- or off-target, works particularly well for neurological diseases because there are over 600 kinds of neurological diseases, all with related phenotypes and genotypes.

Figure 4. a A knowledge network for genes colored according to Louvain-defined modules-

Figure 4. (a) A knowledge network for genes colored according to Louvain-defined modules: Alzheimer’s disease (AD) and dementia (DM) (purple), Huntington’s disease (HD) and Parkinson’s disease (PKD; light blue), depression (MDD) and anxiety (AX; red), schizophrenia (SCZ) and bipolar disorder (BD; green-yellow), and autism (ASD; green). The dashed line in a separates neurodegenerative disorders from psychiatric disorders in the network. (b) The significance of the gene overlap between PNDs. Larger nodes represent PNDs with more genes and thicker edges represent a more significant overlap between PNDs (proportional to −log10p-value of Fisher’s exact test).

Figure 5. (a) A summary of genes connected to PNDs enriched for relevant biological processes (GO) and pathways (KEGG)

Figure 5. (a) A summary of genes connected to PNDs enriched for relevant biological processes (GO) and pathways (KEGG). (b-f) The most significant gene enrichment categories for genes in the modules: (a) Alzheimer’s and dementia (b), Huntington’s disease and Parkinson’s disease (c), depression and anxiety (d), schizophrenia and bipolar disorder (e), and autism (f).

 

An example of a successful repurposed drug campaign for neurological diseases

Recently, the biotech Perlara conducted a successful repurposing campaign: using the drug Epalrestat to treat the congenital disorder PMM2-CDG in a little girl, Maggie. PMM2-CDG falls under the umbrella classification: ‘Congenital disorders of glycosylation (CDG)’, which is a group of over 130 rare metabolic disorders that present a variety of symptoms but commonly have a significant neurological component (NORD, 2021). Notably, the number of patients with a CDG is rapidly increasing. PMM2-CDG specifically affects around 1,000 people worldwide, and while this may seem like a small patient population, it is actually the most common (CDG) (Lyer et al., 2019). 

Perlara, a biotech company based in the Bay Area was working on a different glycosylation disorder (NGLY-1) when they were introduced to Maggie’s parents. Perlara seeks to find cures for rare genetic diseases and the mechanisms behind drug therapies, and so the collaboration between Perlara and Maggie’s Cure (the company Maggie’s family started to find a cure) seemed a perfect fit. 

Perlara initially used a yeast model of PMM2 for testing, but wanted to create a more precise model using C. elegans. That is when Perlara approached InVivo Biosystems – our team was able to create a C. elegans model with high similarity to humans, and conserved mutation sites between worms and humans. 

Equipped with robust models of PMM2 Maggie’sQuest was ready to begin searching for a cure using a drug repurposing approach. The gene-edited model organisms, and patient fibroblasts, were tested with known drugs and compounds, and they found promising results from Epalrestat. 

Epalrestat is a Japanese drug developed in 1992 and used in Japan (never used in the USA) to treat diabetic neuropathy and retinopathy, most commonly in geriatric patients (Maggie’s Cure, 2020; Calabek, Callaghan & Feldman, 2014). Despite this original use, the Perlara team found that Epalrestat also increases enzyme activity. Maggie has now been taking Epalrestat for over a year with no noticeable negative side effects, but with significant improvements in her stability, strength, gross and fine motor skills (Maggie’s Cure, 2021). A 30-patient clinical trial (ages 2-17) began in Spring of 2021. 

Read more about Maggie’s Quest here.

 

Conclusion

The benefits of drug repurposing speak for themselves and are compelling enough that there has been an increase in the number of repurposed drug trials over the past few years: from 2016 to 2020 repurposed drug trials increased 89%, with the rate increasing each year (23% between 2019 and 2020) (Bauzon, Lee & Cummings, 2020). However, there is still a long way to go before repurposing becomes industry standard. Despite the incentives mentioned earlier, two-thirds of drugs are never considered for repurposing (Sahragardjoonegani et al., 2021). And the amount of drugs that are repurposed after the drug is sold commercially (generic entry) is close to zero. This indicates that “the status quo for most drug makers is creating novel one-indication products”, which, while unfortunate, shows a clear way in which improved incentives can increase drug repurposing numbers (Sahragardjoonegani et al., 2021).

Furthermore, drug repurposing is becoming easier, with advancing technology providing more ways to approach repurposing. For example, the University of Chicago has developed an artificial intelligence framework, called Drug Repurposing in Alzheimer’s Disease (DRIAD), which uses machine learning to identify AD drug candidates through a drug library screen? (Albers & Rodriguez, 2021). Once DRIAD nominates potential drug therapies, cell-based models and CRISPR-created model organisms can be used to validate the targets. Thus, drug repurposing offers an affordable, cutting-edge, underutilized strategy to finding treatments for diseases.

 

References

  1. Albers, Mark W. & Rodriguez, Steve (2021). ARTIFICIAL INTELLIGENCE IDENTIFIES CANDIDATES FOR DRUG REPURPOSING IN ALZHEIMER’S DISEASE. Massachusetts General Hospital, Journal. https://advances.massgeneral.org/neuro/journal.aspx?id=1949
  2. Bauzon, J., Lee, G. & Cummings, J. (2020) Repurposed agents in the Alzheimer’s disease drug development pipeline. Alz Res Therapy 12, 98 . https://doi.org/10.1186/s13195-020-00662-x
  3. Bryan, Jenny (2011). How minoxidil was transformed from an antihypertensive to hair-loss drug. The Pharmaceutical Journal, https://pharmaceutical-journal.com/article/news/how-minoxidil-was-transformed-from-an-antihypertensive-to-hair-loss-drug
  4. Butlen-Ducuing, F., Pétavy, F., Guizzaro, L. et al. Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective. Nat Rev Drug Discov 15, 813-814 (2016). https://doi.org/10.1038/nrd.2016.237
  5. Calabek, B., Callaghan, B., & Feldman, E. L. (2014). Therapy for diabetic neuropathy: an overview. Handbook of clinical neurology, 126, 317-333. https://doi.org/10.1016/B978-0-444-53480-4.00022-9
  6. Carmichael, Holly (2021). 1-Year Update. Maggie’s Cure. https://www.maggiescure.com/post/1-year-update
  7. Carmichael, Holly (2020). First Dose! Maggie’s Cure. https://www.maggiescure.com/post/first-dose
  8. Clout, A. E., Della Pasqua, O., Hanna, M. G., Orlu, M., & Pitceathly, R. (2019). Drug repurposing in neurological diseases: an integrated approach to reduce trial and error. Journal of neurology, neurosurgery, and psychiatry, 90(11), 1270-1275. https://doi.org/10.1136/jnnp-2019-320879
  9. Hernandez, J. J., Pryszlak, M., Smith, L., Yanchus, C., Kurji, N., Shahani, V. M., & Molinski, S. V. (2017). Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics. Frontiers in oncology, 7, 273. https://doi.org/10.3389/fonc.2017.00273
  10. Lüscher Dias, T., Schuch, V., Beltrão-Braga, P.C.B. et al. Drug repositioning for psychiatric and neurological disorders through a network medicine approach. Transl Psychiatry 10, 141 (2020). https://doi.org/10.1038/s41398-020-0827-5
  11. Iyer, S., Sam, F. S., DiPrimio, N., Preston, G., Verheijen, J., Murthy, K., Parton, Z., Tsang, H., Lao, J., Morava, E., & Perlstein, E. O. (2019). Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. Disease models & mechanisms, 12(11), dmm040584. https://doi.org/10.1242/dmm.040584
  12. NORD (2021). Congenital Disorders of Glycosylation. NORD (National Organization for Rare Diseases). https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/
  13. Oliveira EAM, Lang KL. Drug Repositioning: Concept, Classification, Methodology, and Importance in Rare/Orphans and Neglected Diseases. J App Pharm Sci, 2018; 8(08): 157-165.
  14. Rudrapal, Mithun,  Khairnar, Shubham J, .&  Jadhav,  Anil G. (2020). Drug Repurposing (DR): An Emerging Approach in Drug Discovery, Drug Repurposing – Hypothesis, Molecular Aspects and Therapeutic Applications, Farid A. Badria, IntechOpen, DOI: 10.5772/intechopen.93193. https://www.intechopen.com/chapters/72744
  15. Sahragardjoonegani, B., Beall, R.F., Kesselheim, A.S. et al. Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. J of Pharm Policy and Pract 14, 3 (2021). https://doi.org/10.1186/s40545-020-00282-8
  16. Wood, Matt (2019).  New treatment options for people with drug-resistant epilepsy, At the Forefront: UChicago Medicine and Biological Sciences Division. https://www.uchicagomedicine.org/forefront/neurosciences-articles/new-treatment-options-for-people-with-drug-resistant-epilepsy
 

About the Author: Alexandra Narin

Alexandra Narin

Alexandra is a Content Marketing Specialist and Grant Writer for InVivo Biosystems. She graduated from the University of St Andrews in 2020 where she earned a Joint MA Honours Degree in English & Psychology/Neuroscience with BPS [British Psychology Society] Accreditation. She has worked as a research assistant, examining the LEC’s (lateral entorhinal cortex) involvement in spatial memory and integrating long term multimodal item-context associations, and completed her dissertation on how the number and kinds of sensory cues affect memory persistence across timescales. Her hobbies include running, boxing, and reading

Share this articles

Facebook
Twitter
Pinterest
LinkedIn
Alexandra Narin

About the Author:

Connect with us